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To understand the role of hypoxia-inducible factor (HIF)-2a in reg-
ulating sensitivity of renal cancer cells to tumor necrosis factor-
related apoptosis inducing ligand (TRAIL)-induced apoptosis,
we transfected wild-type and mutant von Hippel Lindau (VHL)
proteins into TRAIL-sensitive, VHL-negative A498 cells. We ﬁnd
that wild-type VHL, but not the VHL mutants S65W and C162F
that do not degrade HIF proteins, cause TRAIL resistance. Knock
down of the HIF-2a protein by RNA interference (short hairpin
RNA) blocked TRAIL-induced apoptosis, decreased the level of
TRAIL receptor (DR5) protein and inhibited the transcription of
DR5 messenger RNA. By using luciferase constructs containing
the upstream region of the DR5 promoter, we demonstrate that
HIF-2a stimulates the transcription of the DR5 gene by activating
the upstream region between 2448 and 21188. Because HIF-2a is
thought to exert its effect on gene transcription by interacting with
the Max protein partner of Myc in the Myc/Max dimer, small in-
terfering RNAs to Myc were used to lower the levels of this protein.
In multiple renal cancer cell lines decreasing the levels of Myc
blocked the ability of HIF-2a to stimulate DR5 transcription.
PS-341 (VELCADE, bortezomib), a proteasome inhibitor used to
treat human cancer, increases the levels of both HIF-2a and c-Myc
and elevates the level of DR5 in renal cancer, sensitizing renal
cancer cells to TRAIL therapy. Similarly, increasing HIF-2a in
prostate and lung cancer cell lines increased the levels of DR5.
Thus, in renal cancer cell lines expressing HIF-2a,t h i sp r o t e i n
plays a role in regulating the levels of the TRAIL receptor DR5.
Introduction
Renal cell carcinoma (RCC) affects .30 000 individuals each year
and is responsible for .12 000 deaths (1). These tumors are both
radio- and chemoresistant and show minimal therapeutic responses
to interleukin-2, interferon c, tumor-inﬁltrating lymphocytes and
small molecules aimedat inhibiting growth factor receptors,including
epidermalgrowthfactor,vascularendothelialgrowthfactorandplatelet-
derived growth factor receptors (2,3). New therapies are clearly needed
to treat renal cancer.
Tumor necrosis factor-related apoptosis inducing ligand (TRAIL)
is a proapoptotic protein that displays minimal toxicity toward normal
cells, both in vitro and in vivo, and kills a wide spectrum of tumor
types including renal cancer (4–6). TRAIL binds to two receptors,
DR5 (TRAIL-R2) and DR4 (TRAIL-R1) (7), as well as to two re-
ceptors that do not conduct an apoptotic signal, DcR1 and DcR2 (8,9).
Cytotoxic antibodies, lexatumumab, directed at the TRAIL receptor
DR5, when used in an orthotopic metastatic tumor model, decrease the
sizeandmetastaticpotentialofrenaltumorsthatareknowntobesensitive
toTRAILintissueculture(10,11). Resistance to TRAIL in cancer cells,
including prostate and multiple myeloma, can be overcome by the ad-
dition of VELCADE (PS-341), a proteasome inhibitor (12). This agent
functions to increase the number of TRAIL receptors both transcription-
a l l ya n db yp r e v e n t i n gt h e i rd e g r a d a t i o n( 1 2 ) .P S - 3 4 1a l s oe n h a n c e st h e
ability of TRAIL to induce cell death by increasing the levels of BH3
proteins including Noxa, Bik and Bim (13–15). Thus, TRAIL treatment
of renal cancer offers a novel approach to treating this disease.
Although the exact cause of renal cancer is obscure, 60–80% of
RCC have biallelic loss/inactivation of von Hippel Lindau (VHL)
tumor suppressor gene as a consequence of gross genetic loss, non-
sense or missense point mutations and hypermethylation of the VHL
locus (16–18). Because VHL functions as part of Skp1/Cul1/F-box-
like E3 ligase for the hypoxia-inducible factor (HIF) proteins (19,20),
deletion of VHL leads to increased levels of HIF-1a,H I F - 2 a or both
proteins. VHL protein has complex functions unrelated to its regulation
of HIF proteins including a role in the synthesis and degradation of
extracellular cell matrix by affecting the transport of ﬁbronectin (21),
in the regulation of cytoskeletal organization and motility through focal
adhesion formation and in the translocalization of ﬁbroblast growth
factor receptor (22–24). VHL also regulates RNA stability through in-
creasing the level of RNA-binding proteins (25) and messenger RNA
(mRNA) transcription, e.g. the tyrosine hydroxylase gene, by directly
interacting with transcription factors, e.g. Sp1 (26). The suppression of
the nuclear factor-jB pathway by VHL (27) is thought to play a role in
regulating the sensitivity of renal cancercells tovariedapoptoticstimuli.
However, the mechanism by which VHL and HIF proteins control the
sensitivity of renal cancer cells to TRAIL is unknown.
In normoxic conditions following oxygen-dependent prolyl hydrox-
ylation, the HIF proteins are degradedby the proteasome (28). In VHL-
defective RCC cells, the HIF system is activated and a constitutively
hypoxic pattern of gene expression is observed, including increases in
the Bnip3, cyclin D1, transforming growth factor-a and vascular endo-
thelialgrowth factor(29,30)proteins.InRCC,thereisbiastowardHIF-
2a rather than HIF-1a expression (31), and HIF-1a actually inhibits the
action of genes, i.e. b-catenin, that might enhance the growth of certain
tumors (32). Overexpression of HIF-2a increases tumor growth,
whereasHIF-1a appearstohavethereverseeffect(31).Thesetwogenes
have contrasting properties on speciﬁc transcription, with HIF-1a pos-
itively and HIF-2a negatively regulating the Bcl-2-like protein Bnip3
(31). In VHL-defective renal cancer cell lines, cyclin D1 and transform-
i n gg r o w t hf a c t o r - a mRNAs are increased by HIF-2a, whereas in this
model, HIF-1a had little effect on the expression of these genes (31).
Opposite effects on Myc-regulated genes by these two proteins have
also been demonstrated (33,34). However, it is not known how or
whether HIF proteins regulate sensitivity to TRAIL-induced death.
To better understand how TRAIL might be effectively used to treat
renal cancer, we have investigated the role of HIF-2a in the sensitivity
of these tumor cells to TRAIL. We ﬁnd A498 cells that express ele-
vated levels of HIF-2a are sensitive to TRAIL, and overexpression of
VHL or expressionof a short hairpin RNA (shRNA) that decreases the
level of HIF-2a mRNA and protein abrogates this sensitivity. The low
or absent levels of HIF-2a decrease the levels of TRAIL receptor DR5
mRNA and protein, explaining the loss of sensitivity. Small
Abbreviations: cDNA, complementary DNA; GAPDH, glyceraldehyde 3-
phosphate dehydrogenase; GFP, green ﬂuorescent protein; HIF, hypoxia-
inducible factor; mRNA, messenger RNA; PCR, polymerase chain reaction;
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fering RNA; TRAIL, tumor necrosis factor-related apoptosis inducing ligand;
VHL, von Hippel Lindau.
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HIF-2a to stimulate the transcription of this gene in both TRAIL-
sensitive and -resistant cell lines, suggesting that these proteins may
work independently or co-ordinately to regulate HIF-2a. Our data
point to the importance of HIF-2a when present in renal and other
cancer types in controlling the transcription of the DR5 gene.
Materials and methods
Cell lines and reagents
A498, 786-O, Caki-1 and HK-2 cells were purchased from American Type
Culture Collection (Manassas, VA). Cells were maintained in Dulbecco’s mod-
iﬁed Eagle (high glucose) medium supplemented with 10% fetal bovine serum.
Human VHL and HIF-2a genes were polymerase chain reaction (PCR) cloned
into pEGFP-C1 (Clontech, Mountain View, CA) and pCDNA3.0 (Invitrogen,
Carlsbad, CA), respectively. The pCDNA3.1 plasmid containing shRNAs-tar-
geting HIF-2a (shRNA I sense:5#-GCGACAGCTGGAGTATGAA-3# and
shRNA II sense:5#-GAACAGCAAGAGCAGGTTC-3#) was constructed as
described previously (23). Cells were transfected with complementary DNAs
(cDNAs) using Lipofectamine 2000 (Invitrogen) as per the manufacturer’s
instructions, and then FACS sorted for enhanced green ﬂuorescent protein or
Ds-Red. For stable expression of HIF-2a shRNA, A498 cells were selected
with 1.5 lg/ml of G418 (Invitrogen). Recombinant His-tagged human TRAIL
was puriﬁed from bacteria, as described previously (12).
SiRNAs
All siRNAs were purchased from Dharmacon (Lafayette, CO). HIF-2a and Myc
siRNAs were a pool of four siRNAs of the following sequence—siHIF-2a:
GGCAGCACCUCACAUUUGAUU, GAGCGCAAAUGUACCCAAUUU,
GACAAGGUCUGCAAAGGGUUU and GCAAAGACAUGUCCACAGAUU;
siMyc: ACGGAACUCUUGUGCGUAAUU, GAACACACAACGUCUUG-
GAUU, AACGUUAGCUUCACCAACAUU and CGAUGUUGUUUC-UGUG-
GAAUU. HIF-1a siRNA was a pool of two siRNAs of the following
sequence—GAACAAAUACAUGGGAUUAUU and AGAAUGAAGUGUA-
CCCUAAUU. The sequence of the control siRNA was UUCUCCGAACGU-
GUCACGUdTdT.
Apoptosis assay
To examine apoptosis, cells were treated with TRAIL for 16 h in growth
medium. Flow cytometric analysis was done to detect and quantify apoptosis.
Cells were ﬁxed in 70% ethanol and stained with 50 lg/ml propidium iodide in
hypotonic lysis buffer (0.1% sodium citrate and 0.1% Triton X-100) containing
DNase-free RNase A for 30 min. Acquisition and analysis were performed by
FACScan using Cell Quest Alias software (BD Biosciences, San Jose, CA). The
sub-G1 peak was assumed to contain dead or apoptotic cells. The colorimetric
acidphosphataseassaywasperformedtodeterminetheextentofsurvivalofcells
undergoing varied treatments, as follows: a 100 ll aliquot of buffer A [0.1 M
sodium acetate (pH 5.5), 0.1% (vol/vol) Triton X-100 and 10 mM p-nitrophenyl
phosphate (Sigma–Aldrich Chemicals, St Louis, MO)] was added to 100 llo f
cell suspension in a 96-well plate. The plates were placed in the incubator at
37C for 2 h. The reaction was stopped by the addition of 10 ll 1 M NaOH to
each well, and the absorbance of each well was measured at 405 nm using
a microplate reader (Molecular Devices, Sunnyvale, CA).
Chromatin immunoprecipitation assays
Using the chromatin immunoprecipitation assay kit from Millipore according
to the manufacturer’s recommendations direct binding of c-Myc to the DR5
promoter was assessed. In brief, 1   107 A498 cells were ﬁxed in 1% form-
aldehyde for 20 min to cross-link protein–DNA and protein–protein com-
plexes. Chromatin was sheared to an average DNA size of 200–800 bp by
sonication using Cole Palmer ultrasonic cell disrupter (10 times of 10 s pulses
at 30% output using 2 mm tip). The chromatin fragments were immunopreci-
pitated with 4 lg of anti-Myc (sc-768; Santa Cruz Biotechnology, Santa Cruz,
CA) or rabbit IgG (Sigma-Aldrich Chemicals, St Louis, MO) antibodies. Im-
munoprecipitates were washed with the recommended buffers, incubated over-
night at 65C to remove cross-linking and then treated with proteinase K for 2
h. DNA was puriﬁed by phenol–chloroform extraction and ethanol precipita-
tion. DNA samples were analyzed by PCR by using the following pairs of
primers: Myc-BS1, CCGAATGACGCCTGCCCG (forward) and
GGAACGCTCTTATAGTCT (reverse); Myc-BS2, GCGGAGGATTGCGTT-
GAC (forward) and GCGGCTGTACTTTCACTGCC (reverse); Myc-BS3,
GGACCCAGAAACAAACC (forward) and CACCACAGGTTGGTGAC (re-
verse); Myc-BS4, GCGGACTCTGAACCTCAAG (forward) and
GGCTGTGGTTTGTTTCTGG (reserve); Myc-BS5, GCAGGAAGGAAG-
GAAAG (forward) and CTTGAGGTTCAGAGTCCG (reverse); Myc-BS6,
GCTAAGTGTAGCAAGGGTG (forward) and GGACTACAGGCCTGCACC
(reverse); Myc-BS7, GACACAGTACCATGAAGG (forward) and
CTGTGTCCCTGCACCCTTG (reverse) and glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) (control), TACTAGCGGTTTTACGGGCG (forward)
and TCGAACAGGAGGAGCAGAGAGCGA (reverse).
PCR was performed at an annealing temperature of 55C for 30 cycles. The
products were analyzed in 1.5% agarose gel stained with ethidium bromide.
Site-directed mutagenesis
The pGVB2-DR5/ 1188 construct was used as a template for site-directed mu-
tagenesis to inactivate the c-Myc-binding site 5 (Myc-BS5), CAGGTG by PCR.
The following nested primers were used to generate a mutant site (GGATCC):
GAGCTCCCACCAGAAGGAAGAAACTCC (wild-type forward),
CTTCCCAGGGGCGGATCCCCCTTCTGTTC (mutant reverse), GAACA-
GAAGGGGGATCCGCCCCTGGGAAG(mutantforward) andCCATGGCGG-
TAGGGAACGCTCTTATAG (wild-type reverse). The PCR product was cloned
into pGVB2vector via SacI and NcoI sites and the insert veriﬁed by sequencing.
The pcDNA3.1/HIF-2a plasmid was used as a template for PCR to mutate
the HIF-2a shRNA target site (nucleotides 2127–2145, GCGACAGCTGGAG-
TATGAA) using the following nested primers: GAATTCTACCATGCGCTAG
(wild-type forward), GCTTGCTCCTCGTATTCCAGCTGTCGC (mutant re-
verse), GCGACAGCTGGAATACGAGGAGCAAG (mutant forward) and
GAATTCGCGGCCGCTCAGGTGGCCTGGTCCAGG (wild-type reverse).
The mutant PCR fragment with EcoR I and Not I ends was cloned into
pcDNA3.1/HIF-2a plasmid and cut with the same restriction enzymes to yield
a full-length HIF-2a cDNA clone.
Flow cytometric detection for TRAIL receptor expression
The expression levels of DR4 and DR5 were evaluated by ﬂow cytometry.
Cells were seeded in six-well plates at 3   105 per well for 24 h prior to
treatment.After16 h ofincubationwithPS-341(500 nM),cells werecollected,
washed twice with phosphate-buffered saline, incubated at 4C with phycoer-
ythrin-conjugated antibodies recognizing DR4 and DR5 (eBioscience, San
Diego, CA) and then analyzed by ﬂow cytometry.
Quantitative real-time mRNA analysis
Total RNAwas isolated from A498 cells using RNeasy kit (Qiagen, Valencia,
CA) according to the manufacturer’s protocol. The ﬁrst-strand cDNA was
synthesized using Superscript ﬁrst-strand synthesis kit and Oligo (dT) primer
(Invitrogen). Relative quantiﬁcation of DR5 expression was achieved by quan-
titative real-time PCR (iQ5 Multicolor Real-Time PCR detection system, Bio-
Rad Laboratories, Hercules, CA) using iQ5 optical system software. The
expression level of DR5 was normalized to GAPDH. The primers used for
real-time PCR were as follows: DR5 forward ATCACCCAACAAGACCTAGC
and reverse TTCTGAGATATGGTGTCCAGG and GAPDH forward CAGCCT-
CAAGATCATCAGCA and reverse GTCTTCTGGGTGGCAGTGAT.
Luciferase assay
Portions of the DR5 promoter were cloned into the pGVB2 vector that contains
a luciferase reporter (Toyo ink, Tokyo, Japan), a gift of Dr Toshyuki Sakai(35).
Twenty-four hours prior to transfection, A498 or A498-containing HIF-2a
shRNA (0.7   106) was seeded onto 60 mm dishes. Five micrograms of each
plasmid was transfected into these cells using Lipofectamine 2000 (Invitrogen);
and after 48 h, the cells were harvested and assays performed using luciferase
assay reagents (Promega, Madison, WI) and a luminometer (Turner Biosystems,
Sunnyvale, CA). Transfection efﬁciency was normalized by cotransfection of
the pSV-b-galactosidase plasmid (Promega).
Western blotting and antibodies
Forwestern blotting,cells were harvested by scraping,washed with phosphate-
buffered saline and lysed using 1  sodium dodecyl sulfate sample buffer. To
probe western blots, the following antibodies were used according to the man-
ufacturer’s instructions: mouse monoclonal antibodies to VHL (BD Bioscien-
ces), enhancedgreenﬂuorescentprotein(Clontech),HA(Covance,Berkeley,CA),
HIF-1a (BD Biosciences), HIF-2a (Novus Biologicals, Littleton, CO), CXCR4
(EMD Biosciences San Diego, CA), caspase 8 (BD Biosciences), caspase 3
(BD Biosciences), poly ADP ribose polymerase (PARP) (BD Biosciences),
anti-polyhistidine agarose (Sigma), GAPDH (Santa Cruz Biotechnology) and
c-Myc 9E10 (Santa Cruz Biotechnology). The following rabbit polyclonal
antibodies were used: DR5 (Sigma), p21 (Santa Cruz), cyclin D2 (Santa Cruz
Biotechnology) and c-Myc (Santa Cruz Biotechnology).
Results
A498 renal cancer cells, which express high levels of HIF-2a and no
HIF-1a or VHL, are sensitive to TRAIL-induced apoptosis (11). As
HIF-2a regulates TRAIL receptor levels
1735shown by the appearance of a sub-G1 peak on FACS analysis, the
addition of TRAIL to these cells induces apoptosis as early as 4 h,
and 100%of cells are deadby 20 h (Figure 1B).Toexaminethe ability
of HIF-2a to modulate the sensitivity of A498 renal cancer cells to
TRAIL, A498 cells were ﬁrst transiently transfected with a construct
expressing a green ﬂuorescent protein (GFP)–VHL fusion protein and
then FACS sorted for the expression of GFP. The overexpression of
VHL drives down the level of HIF-2a protein (Figure 2A). The GFP-
positive cells were then treated with TRAIL overnight. In comparison
with the wild-type cells (Figure 1A), there was no cleavage of
caspases, PARP or appearance of a sub-G1 peak on FACS analysis
(Figure 2B and C). Transfection of enhanced green ﬂuorescent protein
alone did not inhibit the ability of TRAIL to induce apoptosis (sup-
plementary Figure 1A is available at Carcinogenesis Online). In these
VHL-transfected cells, we see an increase in the number of cells in
the G1 phase of the cell cycle. This result might be secondary to the
induction of p27kip1 or to stabilization of p53 (36,37). Speciﬁc VHL
mutants are expressed in varied tumor types and may or may not
function to regulate the HIF proteins. For example, the S65W and
C162F mutants are common in RCC, but rarely occur in pheochro-
mocytoma, and these proteins do not induce the degradation of the
HIF protein. In comparison, the Y98H and P154L mutant proteins
rarely occur in RCC and induce the degradation of HIF (23). As
above, these cDNAs were transiently transfected as GFP fusions into
Fig. 1. Induction of apoptosis in A498 cells by TRAIL. (A) A498 cells were treated with TRAIL (1 lg/ml) at 37C for 4, 8 and 20 h. Cell lysates collected at each
time point were subjected to western blotting using the indicated antibodies. (B) A498 cells treated with TRAIL were harvested at the indicated time points,
washed three times with phosphate-buffered saline and ﬁxed with 70% ethanol in phosphate-buffered saline for 2 h at 4C. Following ﬁxation, cells were stained
with propidium iodide as described in Materials and Methods to detect the presence of hypodiploid cells (sub-G1 peak) by ﬂow cytometry.
Fig. 2. Inhibition of A498 cell death induced by VHL. (A) A498 cells were transfected with pEGFP-C1 (empty vector) or pEGFP-VHL and (wild-type) vectors.
Forty-eight hours after transfection, cells were washed with phosphate-buffered saline, FACS sorted and enhanced green ﬂuorescent protein (EGFP)-positive cells
retained. These cells were lysed and the extract was western blotted with the indicated antibodies. (B) The enhanced green ﬂuorescent protein-sorted cells were
grown for 24 h at 37C before adding TRAIL (1 lg/ml). At the indicated hours of treatment, cells were harvested, lysed in sodium dodecyl sulfate sample buffer
and the cleavage of caspase 8, caspase 3 and PARP determined by western blot. (C) A portion of the cells were harvested, washed with phosphate-buffered saline
and cell cycle analysis (see legend Figure 1B) done by ﬂow cytometry to detect the presence of a sub-G1 peak.
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1736A498 cells, the cells FACS sorted and then incubated overnight with
TRAIL. The transfection of S65Wand C162F respond to TRAIL with
cell death (supplementary Figure 1B and C is available at Carcino-
genesis Online), whereas those VHL mutants that lead to HIF-2a
degradation function similarly towild-type VHL and make these cells
insensitive to TRAIL killing (supplementary Figure 1D and E is avail-
able at Carcinogenesis Online). Since the level of cell death regulated
by the C162F is more extensive than the S65W mutant, it is possible
that the latter mutant has a slightly increased ability to degrade
HIF-2a protein when compared with C162F, as suggested by the
western blot. These experiments suggest that HIF-2a plays a role in
regulating TRAIL sensitivity in A498 cells.
To examine the ability of HIF-2a to regulate TRAIL-induced cell
death, A498 cells were transfected with a cDNA expression vector
encoding HIF-2a shRNA, and ﬁve clones were generated that con-
tained markedly decreased levels of HIF-2a (Figure 3A). These
clones also expressed decreased levels of the HIF-2a-regulated gene
CXCR4. All the clones expressed decreased levels of DR5 protein on
western blot (Figure 3A). When incubated with TRAIL 1 lg/ml, these
clones showed resistance to TRAIL-induced killing, whereas the pa-
rental cells remained highly sensitive (Figure 3B). To verify that this
was not speciﬁc to a single shRNA, the experiment was repeated with
a second shRNA (see Materials and Methods) with identical results
(supplementary Figure 2A and B is available at Carcinogenesis
Online). To examine the mechanism of HIF-2a action, we carried
out quantitative real-time PCR for DR5 expression on the RNA from
wild-type and cells expressing the HIF-2a shRNA. Results from these
ﬁve clones demonstrated that in the absence of HIF, the levels of DR5
mRNA were markedly decreased (Figure 3C). A498 cells do not
express the second TRAIL receptor DR4.
To attempt to determine whether HIF-2a could regulate the tran-
scription of the DR5 gene, promoter constructs containing different
regions of the DR5 upstream region in front of a luciferase reporter
were transfected into either A498 cells or A498 cells containing
a HIF-2a shRNA. We ﬁnd that in wild-type A498 cells, the region
between  448 and  1188 contains sequences that are essential for
regulation of the transcription of the DR5 promoter (Figure 4). In
comparison, in A498 cells expressing the HIF-2a shRNA, the expres-
sion of these identical promoter constructs was markedly diminished
(Figure 4). Transfection of HIF-2a into cells with decreased HIF-2a
levels overcame the shRNA and stimulated these promoter constructs
(Figure 4), but had little effect when transfected into wild-type cells
(data not shown). Thus, HIF-2a is capable of regulating transcription
of the DR5 promoter.
Recent results from other laboratories demonstrate that HIF-2a
functions by stimulating the activity of the Myc protein through in-
teractions with Myc partner proteins, for example Max (33). This
observation coupled with the existence of multiple potential E-box-
like elements in the upstream region of the DR5 promoter (38), sug-
gested thatthe HIF-2a effects on the DR5promoter might betied toits
interaction with Myc and its partners. To examine this possibility, we
used both siRNA-targeting Myc and a cDNA chimeric construct that
expresses a MadMyc chimera that acts as a dominant-negative protein
(39). As predicted by the transcriptional activity of Myc (33), a de-
crease in this protein (Figure 5A) led to an increase in p21 levels and
a decrease in cyclin D2 (Figure 5A). Overexpression of HIF-2a (Fig-
ure5B)inoneoftheA498clonesexpressingtheshRNA-targetingHIF-
2a increased HIF-2a expression and induced transcription from the
DR5 ( 1188) promoter (Figure 5B). To carry out these experiments
(Figure 5A and B), a mutation was placed in the HIF-2a coding
sequence (HIF-2a Mut) so that this mRNA could not be recognized
by the shRNA. This stimulation was reversed both by the transfection
of Myc siRNA and the dominant-negative MadMyc cDNA construct
(Figure 5B), suggesting that the transcriptional regulation of DR5
involved both HIF-2a and Myc proteins. To determine the exact site
of c-Myc binding to DR5 promoter, chromatin immunoprecipitation
analysis was done focused on seven E-box-like sites identiﬁed pre-
viously (38), using the known c-Myc-binding site inGAPDH asa con-
trol. Results from this experiment demonstrate that the sequence
GTGGAA from  532 to  537 is capable of binding c-Myc when
compared with the IgG control. All other sites demonstrated similar
binding to the control. To examine whether this site regulated tran-
scriptional activation of the DR5 promoter by c-Myc, it was mutated
in the DR5 promoter luciferase construct and this construct was trans-
fected into A498 cells. Mutation of this sequence markedly decreased
the baseline activity of the promoter (Figure 5D).
Fig. 3. HIF-2a shRNA decreases the level of DR5 mRNA and protein.
(A) A498 cell lines containing scrambled shRNA (A498 clone C), HIF-2a
shRNA I (clones 1–5), pcDNA3.1 vector alone or HIF-2a shRNA
I-containing cells transfected with the wild-type HIF-2a cDNA were
homogenized and extracts subjected to sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and western blotted with antibodies to
HIF-2a, DR5 and CXCR4and GAPDHas a loadingcontrol. (B) A498clones
containing scrambled shRNA or HIF-2a shRNA I were treated with TRAIL
(1 lg/ml) for varying time periods and percent viability measured by the acid
phosphatase assay as described in Materials and Methods. Each assay is
performed in triplicate and the standard error of the mean is shown. (C)R N A
was extracted from these A498 clones and subjected to quantitative real-time
PCR to measure the levels of the DR5 mRNA using GAPDH as an internal
control. The experiment was performed in triplicate and the standard error of
the mean is shown.
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which is used to treat patients with cancer, sensitizes prostate cancer
cells to TRAIL-induced cell death by regulating the level of the DR5
receptor mRNA and protein (12). To examine whether the HIF shRNA-
containing A498 cells would respond similarly, these cells were treated
overnight with TRAIL (1 lg/ml) or PS-341 (0.5 lM) alone or in com-
bination. PS-341 treatment greatly sensitized these cells with low levels
of HIF-2a to TRAIL-induced cell death (supplementary Figure 3A is
available at Carcinogenesis Online) and, as demonstrated by FACS anal-
ysis of two different HIF-2a shRNA-containing clones, this affect is
correlated with an increase in TRAIL receptors (supplementary Fig-
ure 3B is available at Carcinogenesis Online). Similar results were
obtained with MG-132, another proteasome inhibitor (data not
shown). As demonstrated by western blots (supplementary Figure
3C is available at Carcinogenesis Online), the increase in DR5 recep-
tors induced by PS-341 is correlated with an increase in both Myc and
HIF-2a proteins in both the control and two clones that were exam-
ined. This proteasome-induced increase in HIF-2a was reversed when
additional siRNA to HIF-2a was transfected into these cells, suggest-
ing that regulation of the level of HIF-2a mRNA might be important
to the PS-341 activity.
To examine whether regulation of DR5 transcription by HIF-2a can
be generalized to other renal cell cancer cell lines, we studied the
affect of siRNA to HIF-2a and Myc on the level of DR5 in PV-10
and RCC4 renal cancer cell lines. Both of these cell lines contain
HIF-1a and -2a but no VHL, and in comparison with A498, are
relatively insensitive to TRAIL-induced apoptosis. Transfection of
HIF-2a siRNA decreased the level of HIF-2a in RCC4 (Figure 6A)
and PV-10 (data not shown). Even in the presence of unchanged levels
of HIF-1a, a decrease in HIF-2a inhibited the transcription of the DR5
( 1188)-Luc plasmid in both cell lines. Likewise, both Myc siRNA
and the MadMyc cDNA transfections decrease the levels of DR5
protein and transcription (Figure 6A and B). To attempt to determine
whether HIF-2a was important in other tumor cell lines in controlling
DR5 levels, A549 lung and PC3 prostate cancer cell lines were placed
in hypoxia to induce an increase in HIF-2a levels (Figure 6C). West-
ern blots demonstrate that this increase in HIF-2a levels was accom-
panied by a parallel increase in DR5 protein. Knock down of HIF-2a
using two different siRNAs inhibited this increase in hypoxia-driven
changes in DR5. To evaluate the importance of HIF-1a levels to the
control of DR5 transcription, this protein was decreased by two dif-
ferent siRNAs (Figure 6D) and the  1188 DR5 promoter construct
was transfected into these cells. In contrast to HIF-2a, lowering the
level of HIF-1a did not decrease the luciferase output from the up-
stream elements of the DR5 promoter (Figure 6E).
Discussion
Our data suggest that HIF-2a protein plays an important role in reg-
ulating the levels of DR5 receptors in renal carcinoma cells that
express this protein. The ability of HIF-2a to control the level of
the TRAIL receptor DR5 does not appear to be limited to TRAIL-
sensitive cell lines. siRNAs targeted at HIF-2a decrease the expres-
sion of the TRAIL receptor mRNA and protein when transfected into
the TRAIL-resistant PV-10 and RCC4 cell lines as well as the TRAIL-
sensitive A498 cells. Nor is this effect limited to renal cancer cells
since we see similar results in A549 lung and PC3 prostate cancer cell
lines when they are placed in hypoxia. In contrast, lowering the level
of HIF-1a did not decrease either the level of the DR5 protein or
transcription from the DR5 promoter. Additionally, renal cancer Caki
cells, which express only VHL, when placed in relative hypoxia in-
duce increased levels of HIF-1a but do not increase either DR5 tran-
scription or protein levels (data not shown). Although HIF-2a plays an
important role in regulating the level of DR5, renal cancer cells con-
taining this protein are both sensitive and resistant to TRAIL-induced
apoptosis,suggestingthatsensitivitytoTRAILiscontrolledbyacom-
plex set of proteins other than the receptor.
Previously, we have shown that PS-341 increases DR5 levels both
by inhibiting protein destruction and by increasing DR5 transcription.
In renal cancer cells with low HIF-2a levels, we ﬁnd that PS-341
treatment increases both the level of DR5 protein and sensitivity to
TRAIL-induced apoptosis. The affect of this drug is correlated with
its ability to increase the levels of both HIF-2a and Myc, two proteins
that appear to regulate DR5 transcription. It is possible that PS-341
increases HIF-2a mRNA levels since transfection of siRNA to HIF-2a
blocks this compound’s ability to increase protein levels. Trials of
PS-341 in humans with renal cancer have yielded varying results. In
one study (40), there was little single-agent activity, whereas in a sec-
ond trial, stable disease was seen in 14 patients with 4 patients having
a partial response (41). The combination of PS-341 and TRAIL may
have utility in treating renal cancer.
The clear differences between HIF-1a and -2a appear to be found
in multiple cells models. Most recently, HIF-1a has been shown to
inhibit the function of the Myc protein (34,42). In keeping with the
antagonism of Myc, HIF-1a decreases Myc-activated genes including
hTERT and BRCA1 (42). HIF-2a has the exact opposite effect (33)
enhancing Myc-induced transformation of ﬁbroblasts and promoting
cell cycle progression of hypoxic renal carcinoma cells. HIF-1a has
been shown to retard tumor growth, whereas HIF-2a stimulates the
growth of tumors (31). If in embryonic stem cells the HIF-1a gene is
replaced by HIF-2a, the resulting teratomas have increased expres-
sion of transforming growth factor-a, vascular endothelial growth
factor and cyclin D1 (43). Using microarray analysis, HIF-1a but
not HIF-2a has been shown to regulate the levels of glycolytic genes
(44). Thus, it is not surprising that HIF-1a and HIF-2a appear to
regulate DR5 levels differently. Although there is not a consensus-
binding site for HIF-1 (5#G/ACGTG3#) (45) in the DR5 promoter,
complex regulation of this promoter by HIF-2a and Myc/Max is
possible.
Fig. 4. DR5 promoter activity detected by luciferase assay. A498 clones
were transfected with the pGVB2-based reporter plasmids (5 lg DNA per
60 mm dish) containing various lengths of 5#-human DR5 promoter gene
(see reporter plasmid structure). Ten microliters of each cell lysate (protein
concentration: 5 lg/ll) was used to determine luciferase activity that the
values obtained were normalized by assaying the activity of a cotransfected
pSV-b-galactosidase plasmid. The data shown are the mean with the standard
error from the mean of three independent transfections.
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TRAIL through multiple mechanisms. For example, Nieminen et al.
(46) found that Myc primed mitochondria by a mechanism involving
activation of Bak, enabling weak TRAIL signals to stimulate the
mitochondrial pathway. Myc has also been found to decrease the
TRAIL-induced increases (47) in Mcl-1 and cIAP2 by inhibition of
nuclear factor-jB thus sensitizing the cell to the intrinsic pathway.
Increasing the cellular levels of Myc has been shown to upregulate the
level of DR5 protein whereas transfection of the dominant-negative
MadMyc protein decreases the level of this protein (39). Myc appears
to control the transcription of DR5 (39) and there is data to either
support an indirect control of transcription (39) or direct control by
binding to non-canonical E-boxes (38). We have demonstrated that
Myc is capable of binding to the E-box between  532 and  537 in
the DR5 promoter and mutation of this site decreases the activity of the
DR5 promoter in A498 cells. HIF-2a has been shown to enhance the
binding of Myc to gene promoters by increasing the levels of Myc/Max
(33) or by directly binding to the E-Box as a HIF-2a–Max complex.
Indirect regulation of DR5 transcription could arise from the ability of
Myc to control protein synthesis through regulation of ribosomal pro-
teins thatmay leadtothe production oftranscriptionfactorsthatbind to
the DR5 promoter [for review see ref. (48)]. HIF is also capable of
Fig. 5. DecreasingMyc proteinlevelsregulates HIF-2a controlof DR5 transcription. (A) Western blot ofextracts from A498 cells studied in (B) were probed with
antibodiesto Myc, HIF-2a, p21, cyclin D2 or GAPDHas a loadingcontrol. (B) Regulationof DR5 promoter activity in A498 HIF-2a-knockdowncells. A498 cells
containing HIF-2a shRNAwere transfected with DR5 promoter construct ( 1188) with or without the cDNA expressing HIF-2a Mut, MYC siRNA or MadMyc
protein were assayed after 48 h. HIF-2a Mut contains a mutation (see Materials and Methods) in the coding sequence so it cannot be recognized by the shRNA.
Luciferase activity was obtained using 5 lg of cell protein lysate that was normalized to cotransfected pSV-b-galactosidase plasmid. The luciferase values shown
are the mean ± SD from three independent observations. (C) Schematic representation of the human DR5 promoter with seven non-canonical E-box elements is
shown. The speciﬁc primers for each element used in the PCR in chromatin immunoprecipitation assay are described in the Materials and Methods. The sizes (bp)
ofthe ampliﬁedregionsforBS1–BS7are 182,130,143,145,141,154 and112,respectively. Acontrolreactionshown demonstrates c-Mycbindingto a knownsite
in GAPDH. The speciﬁcity of binding of c-Myc to each site is shown as the fold difference between c-Myc immunoprecipitation and rabbit IgG control
(background) as demonstrated by densitometry. (D) The effect ofmutationin the BS5 region on DR5 baselinepromoteractivity. A498 cells were transfected for48
hwithwild-typeorE-boxmutantDR5/ 1188promoterconstructs. Theluciferaseactivitywasmeasuredbyusing5 lgofcell proteinlysateandvaluesnormalized
to cotransfected pSV-b-galactosidase plasmid. The luciferase values shown are the mean ± SD from three independent observations.
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or both could regulate the DR5 promoter by indirectly controlling the
production of proteins that in turn stimulate this promoter. In summary,
these data are the ﬁrst to demonstrate the role of HIF-2a and Myc
together in regulating the levels of the TRAIL receptor DR5.
Supplementary material
Supplementary Figures 1–3 can be found at http://carcin.oxfordjournals.
org/
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